Total Payments
$38,502
2024 Payments
$4,502
Companies
22
Transactions
191
Medicare Patients
10,972
Medicare Billing
$16.9M
Payment Breakdown by Category
Consulting$28,133 (73.1%)
Food & Beverage$6,083 (15.8%)
Research$2,052 (5.3%)
Other$1,228 (3.2%)
Travel$991.22 (2.6%)
Education$14.13 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $28,133 | 11 | 73.1% |
| Food and Beverage | $6,083 | 172 | 15.8% |
| Unspecified | $2,052 | 3 | 5.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,228 | 2 | 3.2% |
| Travel and Lodging | $991.22 | 2 | 2.6% |
| Education | $14.13 | 1 | 0.0% |
Payments by Type
General
$36,450
188 transactions
Research
$2,052
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $15,233 | 61 | $0 (2024) |
| Genentech, Inc. | $12,814 | 14 | $0 (2024) |
| F. Hoffmann-La Roche AG | $3,280 | 5 | $0 (2023) |
| Ocular Therapeutix, Inc. | $3,171 | 3 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $933.92 | 31 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $687.70 | 1 | $0 (2023) |
| Allergan, Inc. | $503.19 | 20 | $0 (2021) |
| Alimera Sciences, Inc. | $379.88 | 9 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $280.34 | 4 | $0 (2024) |
| Astellas Pharma US Inc | $214.07 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,502 | 32 | Ocular Therapeutix, Inc. ($3,171) |
| 2023 | $3,056 | 30 | F. Hoffmann-La Roche AG ($1,484) |
| 2022 | $1,719 | 18 | Genentech, Inc. ($1,178) |
| 2021 | $4,723 | 21 | Genentech, Inc. ($3,694) |
| 2020 | $4,966 | 14 | Genentech USA, Inc. ($2,386) |
| 2019 | $449.03 | 18 | Allergan Inc. ($286.87) |
| 2018 | $10,716 | 29 | Genentech USA, Inc. ($5,244) |
| 2017 | $8,371 | 29 | Genentech USA, Inc. ($6,368) |
All Payment Transactions
191 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $32.54 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/20/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $27.18 | General |
| Category: EYE CARE | ||||||
| 09/24/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $124.26 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/23/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: Ophthalmology | ||||||
| 09/16/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: EYE CARE | ||||||
| 09/10/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $29.44 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/28/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $38.03 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/08/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,865.00 | General |
| 07/23/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/20/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $10.21 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/19/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $68.16 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/19/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $54.26 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/18/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $34.77 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/18/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $10.75 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/17/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $208.89 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 07/17/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $64.48 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/08/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/27/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: Ophthalmology | ||||||
| 06/24/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Ophthalmology | ||||||
| 06/18/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $96.66 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 06/17/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $29.38 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/28/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: EYE CARE | ||||||
| 05/08/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $30.26 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/30/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 04/23/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $124.09 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| VA2 PhIII Yosemite | F. Hoffmann-La Roche AG | $1,484 | 2 |
| A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA YOSEMITE, A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867461 IN PATIENTS WITH DIABETIC MACULAR EDEMA RHINE | F. Hoffmann-La Roche AG | $568.64 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 2,930 | 36,628 | $13.3M | $3.9M |
| 2022 | 14 | 2,733 | 19,319 | $10.8M | $4.0M |
| 2021 | 15 | 2,601 | 17,938 | $11.2M | $4.5M |
| 2020 | 13 | 2,708 | 17,882 | $10.9M | $4.5M |
Total Patients
10,972
Total Services
91,767
Medicare Billing
$16.9M
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 222 | 2,480 | $3.7M | $1.7M | 45.5% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 49 | 21,840 | $2.3M | $619,693 | 26.4% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 110 | 3,065 | $1.5M | $544,585 | 36.1% |
| J3490 | Unclassified drugs | Office | 2023 | 57 | 203 | $1.4M | $374,438 | 26.8% |
| 67028 | Injection of drug into eye | Office | 2023 | 408 | 2,164 | $2.2M | $197,029 | 9.1% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 35 | 854 | $1.1M | $185,867 | 16.5% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 27 | 855 | $374,490 | $101,387 | 27.1% |
| 92134 | Imaging of retina | Office | 2023 | 885 | 3,110 | $233,106 | $86,683 | 37.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 524 | 1,318 | $223,975 | $82,460 | 36.8% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 315 | 365 | $87,600 | $29,192 | 33.3% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 191 | 191 | $54,802 | $18,853 | 34.4% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 12 | 12 | $78,648 | $10,358 | 13.2% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 59 | 59 | $15,062 | $5,530 | 36.7% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 22 | 98 | $14,700 | $5,390 | 36.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 14 | 14 | $5,712 | $475.93 | 8.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 205 | 2,788 | $4.1M | $2.0M | 47.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 162 | 5,584 | $2.7M | $1.2M | 44.5% |
| J3490 | Unclassified drugs | Office | 2022 | 32 | 167 | $775,000 | $305,589 | 39.4% |
| 67028 | Injection of drug into eye | Office | 2022 | 382 | 2,265 | $2.3M | $205,852 | 9.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 26 | 3,660 | $402,600 | $109,219 | 27.1% |
| 92134 | Imaging of retina | Office | 2022 | 851 | 3,190 | $238,853 | $88,865 | 37.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 439 | 886 | $144,924 | $55,773 | 38.5% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 307 | 346 | $78,415 | $27,608 | 35.2% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 185 | 185 | $49,517 | $18,209 | 36.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 77 | 78 | $19,804 | $6,474 | 32.7% |
About Dr. John Wells, MD
Dr. John Wells, MD is a Ophthalmology healthcare provider based in West Columbia, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1841289154.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Wells, MD has received a total of $38,502 in payments from pharmaceutical and medical device companies, with $4,502 received in 2024. These payments were reported across 191 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($28,133).
As a Medicare-enrolled provider, Wells has provided services to 10,972 Medicare beneficiaries, totaling 91,767 services with total Medicare billing of $16.9M. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location West Columbia, SC
- Active Since 10/19/2005
- Last Updated 04/03/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1841289154
Products in Payments
- Non-Covered Product (Drug) $13,801
- Lucentis (Biological) $8,245
- EYLEA (Biological) $1,079
- Vabysmo (Drug) $611.76
- EYLEA HD (Biological) $532.33
- OZURDEX (Drug) $505.34
- DEXTENZA (Drug) $305.55
- ACTHAR (Biological) $238.65
- YUTIQ (Drug) $219.91
- Iluvien (Drug) $170.24
- Izervay (Drug) $166.77
- Syfovre (Drug) $156.19
- BEOVU (Drug) $110.84
- XEN (Device) $96.58
- Tecnis 1-piece IOL (Device) $92.47
- Bromsite (Drug) $90.51
- VABYSMO (Drug) $86.13
- ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM (Device) $76.26
- TearLab Osmolarity System (Device) $45.86
- Actemra (Biological) $30.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in West Columbia
William Clark, Md, MD
Ophthalmology — Payments: $1.0M
Ophthalmology $1.0M
Bethany Bray, M.d, M.D
Ophthalmology — Payments: $11,414
Ophthalmology $11,414
Teresa Fowler, Md, MD
Ophthalmology — Payments: $4,971
Ophthalmology $4,971
Dr. John Payne, Md, MD
Ophthalmology — Payments: $1,527
Ophthalmology $1,527
Nitin Nigam, Md, MD
Ophthalmology — Payments: $1,378
Ophthalmology $1,378
David Johnson, Md, MD
Ophthalmology — Payments: $1,034
Ophthalmology $1,034